A drug interaction study assessing the effects of cyp3a4 inhibition on the pharmacokinetics of levadex™ (map0004 orally inhaled dhe) in healthy volunteers

被引：0
|
作者：
Forst, A. [1 ]
Kellerman, D. [1 ]
Kori, S. [1 ]
Febbraro, S. [2 ]
WuTann, L. [2 ]
Thomas, T. [2 ]
Taylor, G. [3 ]
机构：
[1] MAP Pharmaceut Inc, Mountain View, CA USA
[2] Simbec Res Ltd, Merthyr Tydfil, M Glam, Wales
[3] Penreka Ltd, Radyr, Wales
来源：
CEPHALALGIA | 2011年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PS1-146
引用
收藏
页码：81 / 82
页数：2
相关论文
共 44 条
  • [1] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX™ (MAP0004, Orally Inhaled DHE) in Healthy Volunteers
    Forst, A.
    Kellerman, D.
    Kori, S.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    HEADACHE, 2011, 51 : 20 - 20
  • [2] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of LEVADEX™ (MAP0004, orally inhaled dihydroergotamine) in Healthy Volunteers
    Kellerman, Don
    Forst, Amy
    Kori, Shashidhar
    Febbraro, Salvatori
    WuTann, Lan
    Thomas, Tracy
    Taylor, Glyn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1365 - 1366
  • [3] A Drug Interaction Study Assessing the Effects of CYP3A4 Inhibition on the Pharmacokinetics of MAP0004, an Orally Inhaled Formulation of Dihydroergotamine in Healthy Volunteers
    Forst, Amy
    Kellerman, Don
    Kori, Shashidhar
    Febbraro, Salvatori
    Tann, Lan
    Thomas, Tracy
    Taylor, Glyn
    NEUROLOGY, 2012, 78
  • [4] Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans
    Kellerman, D.
    Kori, S.
    Forst, A.
    Chang, J.
    Febbraro, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    Dodick, D. W.
    CEPHALALGIA, 2012, 32 (02) : 150 - 158
  • [5] Assessing the Consistency of LEVADEX™ (MAP0004, Orally Inhaled Dihydroergotamine) Pharmacokinetic Parameters in Healthy Volunteers: Results from 3 Clinical Studies
    Forst, Amy
    Iwashita, Julie
    Kellerman, Don
    Kori, Shashidhar
    Thomas, Tracy
    Taylor, Glyn
    ANNALS OF NEUROLOGY, 2011, 70 : S64 - S64
  • [6] ASSESSING THE CONSISTENCY OF LEVADEX™ (MAP0004, ORALLY INHALED DIHYDROERGOTAMINE) PHARMACOKINETIC PARAMETERS IN HEALTHY VOLUNTEERS: RESULTS FROM 3 CLINICAL STUDIES
    Frost, A.
    Kellerman, D.
    Kori, S.
    Thomas, T.
    Taylor, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 197 - 197
  • [7] Assessment of the consistency of pharmacokinetic parameters of levadex™ (map0004, orally inhaled dihydroergotamine) in healthy volunteers - results from 3 clinical studies
    Forst, A.
    Iwashita, J.
    Kellerman, D.
    Kori, S.
    Thomas, T.
    Taylor, G.
    CEPHALALGIA, 2011, 31 (01) : 82 - 82
  • [8] Assessment of the Consistency of Pharmacokinetic Parameters of LEVADEX™ (MAP0004, Orally Inhaled Dihydroergotamine) in Healthy Volunteers - Results from 3 Clinical Studies
    Forst, A.
    Iwashita, J.
    Kellerman, D.
    Kori, S.
    Thomas, T.
    Taylor, G.
    HEADACHE, 2011, 51 : 22 - 22
  • [9] An Open-Label, 2-Period, Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX™ (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45®) in Smoking and Non-Smoking Adult Volunteers
    Forst, Amy
    Febbraro, Salvatori
    Kellerman, Don
    Kori, Shashidhar
    Tann, Lan
    Thomas, Tracy
    NEUROLOGY, 2011, 76 (09) : A197 - A197
  • [10] An Open-Label, Two-Period Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX™ (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45®) in Smoking and Non-Smoking Adult Volunteers
    Forst, A.
    Febbraro, S.
    Kellerman, D.
    Kori, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    HEADACHE, 2011, 51 : 17 - 17
12345